Therapeutic potential of adult bone marrow-derived mesenchymal stem cells in prostate cancer bone metastasis

Clinical Cancer Research

Volumn 15, Issue 23, 2009, Pages 7175-7185

  Chanda, Diptiman ^a   Isayeva, Tatyana ^a   Kumar, Sanjay ^a   Hensel, Jonathan A ^a   Sawant, Anandi ^a   Ramaswamy, Girish ^b   Siegal, Gene P ^a   Beatty, Matthew S ^a   Ponnazhagan, Selvarangan ^a  

^a University of Alabama at Birmingham   (United States)

^b and Radiation Oncology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OSTEOPROTEGERIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLUMINESCENCE; BONE ATROPHY; BONE METASTASIS; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MICRO-COMPUTED TOMOGRAPHY; MORPHOMETRICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER;

ANIMALS; BONE MARROW CELLS; CELL LINE, TUMOR; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MESENCHYMAL STEM CELLS; MICE; MICE, SCID; NEOPLASM METASTASIS; OSTEOCLASTS; OSTEOPROTEGERIN; PROSTATIC NEOPLASMS; TIBIA; TISSUE THERAPY; X-RAY MICROTOMOGRAPHY;

EID: 73149125525     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-1938     Document Type: Article

References (29)

1. Jemal A, Siegel R, Ward E, Murray T, Xu H, Thun MJ. Cancer statistics. CA Cancer J Clin 2007;57:43-66.
2. Roudier MP, Morrissey C, True LD, Higano CS, Vessella RL, Ott SM. Histopathological assessment of prostate cancer bone osteoblastic metastases. J Urol 2008;180:1154-60.
3. Ye L, Kynaston HG, Jiang WG. Bone metastasis in prostate cancer: molecular and cellular mechanisms. Int J Mol Med 2007;20:103-11.
4. Guise TA, Yin JJ, Mohammad KS. Role of endothelin-1 in osteoblastic bone metastases. Cancer 2003;97:779-84.
5. Choueiri MB, Tu SM, Yu-Lee LY, Lin SH. The central role of osteoblasts in the metastasis of prostate cancer. Cancer Metastasis Rev 2006;25:601-9.
6. Blair JM, Zhou H, Seibel MJ, Dunstan CR. Mechanisms of disease: roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis. Nat Clin Pract Oncol 2006;3:41-9.
7. Wittrant Y, Theoleyre S, Chipoy M, et al. RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis. Biochim Biophys Acta 2004;1704:49-57.
8. Dougall WC, Chaisson M. The RANK/RANKL/OPG triad in cancer-induced bone diseases. Cancer Metastasis Rev 2006;25:541-9.
9. Whang PG, Schwarz EM, Gamradt SC, Dougall WC, Lieberman JR. The effects of RANK blockade and osteoclast depletion in a model of pure osteoblastic prostate cancer metastasis in bone. J Orthop Res 2005;23:1475-83.
10. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-19.
11. Chanda D, Isayeva T, Kumar S, et al. Systemic osteoprotegerin gene therapy restores tumor-induced bone loss in a therapeutic model of breast cancer bone metastasis. Mol Ther 2008;16:871-8.
12. Holen I, Shipman CM. Role of osteoprotegerin (OPG) in cancer. Clin Sci (Lond) 2006;110:279-91.
13. Onyia JE, Galvin RJ, Ma YL, et al. Novel and selective small molecule stimulators of osteoprotegerin expression inhibit bone resorption. J Pharmacol Exp Ther 2004;309:369-79.
14. Vanderkerken K, De Leenheer E, Shipman C, et al. Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma. Cancer Res 2003;63:287-9.
15. Zhang J, Dai J, Qi Y, et al. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 2001;107:1235-44.
16. Morony S, Capparelli C, Sarosi I, Lacey DL, Dunstan CR, Kostenuik PJ. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res 2001;61:4432-6.
17. Capparelli C, Kostenuik PJ, Morony S, et al. Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy. Cancer Res 2000;60:783-7.
18. Kumar S, Chanda D, Ponnazhagan S. Therapeutic potential of genetically modified mesenchymal stem cells. Gene Ther 2008;15:711-15.
19. Studeny M, Marini FC, Dembinski JL, et al. Mesenchymal stem cells: potential precursors for tumor stroma and targeted delivery vehicles for anticancer agents. J Natl Cancer Inst 2004;96:1593-603.
20. Nakamura K, Ito Y, Kawano Y, et al. Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. Gene Ther 2004;11:1155-64.
21. Tropel P, Noël D, Platet N, Legrand P, Benabid AL, Berger F. Isolation and characterisation of mesenchymal stem cells from adult mouse bone marrow. Exp Cell Res 2004;295:395-406.
22. Kumar S, Ponnazhagan S. Bone homing of mesenchymal stem cells by ectopic α4 integrin expression. FASEB J 2007;21:3917-27.
23. Holen I, Croucher PI, Hamdy FC, Eaton CL. Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. Cancer Res 2002;62:1619-23.
24. Fritz V, Noël D, Bouquet C, et al. Antitumoral activity and osteogenic potential of mesenchymal stem cells expressing the urokinase-type plasminogen antagonist amino-terminal fragment in a murine model of osteolytic tumor. Stem Cells 2008;26:2981-90.
25. Dotan ZA. Bone imaging in prostate cancer. Nat Clin Pract Urol 2008;5:434-44.
26. Kingsley LA, Fournier PG, Chirgwin JM, Guise TA. Molecular biology of bone metastasis. Mol Cancer Ther 2007;6:2609-17.
27. Guise TA, Mohammad KS, Clines G, et al. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res 2006;12:6213-6.
28. Hiraga T, Kizaka-Kondoh S, Hirota K, Hiraoka M, Yoneda T. Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer. Cancer Res 2007;67:4157-63.
29. Nyambo R, Cross N, Lippitt J, et al. Human bone marrow stromal cells protect prostate cancer cells from TRAIL-induced apoptosis. J Bone Miner Res 2004;19:1712-21.